These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35110395)

  • 1. Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research.
    Levine AJ
    Cancer Res; 2022 Feb; 82(3):362-364. PubMed ID: 35110395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating p53 into the clinic.
    Cheok CF; Verma CS; Baselga J; Lane DP
    Nat Rev Clin Oncol; 2011 Jan; 8(1):25-37. PubMed ID: 20975744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible.
    El-Deiry WS
    Cancer Res; 2023 Apr; 83(7):979-982. PubMed ID: 37014041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting TP53 in mouse models of human cancers.
    Parant JM; Lozano G
    Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational processes shape the landscape of TP53 mutations in human cancer.
    Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
    Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
    Kashofer K; Regauer S
    Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in p53 research: an interdisciplinary perspective.
    Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
    Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation, mitochondria and cancer.
    Kamp WM; Wang PY; Hwang PM
    Curr Opin Genet Dev; 2016 Jun; 38():16-22. PubMed ID: 27003724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.